Inspire Investing LLC trimmed its holdings in shares of Encompass Health Corporation (NYSE:EHC - Free Report) by 9.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 29,376 shares of the company's stock after selling 3,020 shares during the period. Inspire Investing LLC's holdings in Encompass Health were worth $2,975,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. WPG Advisers LLC bought a new position in shares of Encompass Health during the 1st quarter worth about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Encompass Health by 749.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 416 shares of the company's stock valued at $42,000 after purchasing an additional 367 shares during the last quarter. Arlington Trust Co LLC lifted its holdings in Encompass Health by 22.9% during the 1st quarter. Arlington Trust Co LLC now owns 671 shares of the company's stock valued at $68,000 after purchasing an additional 125 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Encompass Health by 19.0% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 720 shares of the company's stock valued at $73,000 after purchasing an additional 115 shares during the last quarter. Finally, SVB Wealth LLC bought a new position in Encompass Health during the 1st quarter valued at about $84,000. 97.25% of the stock is owned by institutional investors.
Insider Activity at Encompass Health
In other news, EVP Patrick William Tuer sold 1,020 shares of Encompass Health stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $123.59, for a total transaction of $126,061.80. Following the completion of the sale, the executive vice president owned 18,846 shares in the company, valued at $2,329,177.14. The trade was a 5.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 2.00% of the stock is currently owned by corporate insiders.
Encompass Health Trading Up 1.8%
Shares of NYSE EHC opened at $126.89 on Friday. Encompass Health Corporation has a 1-year low of $87.85 and a 1-year high of $126.90. The company has a market cap of $12.78 billion, a PE ratio of 24.83, a P/E/G ratio of 2.18 and a beta of 0.92. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.76. The company has a 50-day moving average of $117.36 and a two-hundred day moving average of $112.58.
Encompass Health (NYSE:EHC - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $1.40 earnings per share for the quarter, topping analysts' consensus estimates of $1.20 by $0.20. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same period in the previous year, the firm posted $1.11 earnings per share. The company's revenue was up 12.0% on a year-over-year basis. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. As a group, equities analysts expect that Encompass Health Corporation will post 4.8 earnings per share for the current fiscal year.
Encompass Health Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Wednesday, October 1st will be paid a $0.19 dividend. This is a boost from Encompass Health's previous quarterly dividend of $0.17. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Wednesday, October 1st. Encompass Health's payout ratio is presently 13.31%.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on EHC. Stephens raised shares of Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price target for the company in a report on Thursday, June 5th. Wall Street Zen downgraded shares of Encompass Health from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. UBS Group lifted their price target on shares of Encompass Health from $130.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Bank of America lifted their price target on shares of Encompass Health from $145.00 to $160.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Truist Financial lifted their price target on shares of Encompass Health from $135.00 to $140.00 and gave the company a "buy" rating in a report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. According to data from MarketBeat.com, Encompass Health currently has a consensus rating of "Buy" and a consensus price target of $137.71.
Check Out Our Latest Stock Report on EHC
About Encompass Health
(
Free Report)
Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
